26 research outputs found
Zu den Entscheidungswirkungen von Paragraph 613a BGB vor und nach Insolvenz
Bibliothek Weltwirtschaft Kiel C 139634 / FIZ - Fachinformationszzentrum Karlsruhe / TIB - Technische InformationsbibliothekSIGLEDEGerman
Assessment of adrenocortical function in the critically ill
The assessment of adrenocortical function in the critically ill continues to be a source of controversy. In this review we discuss the physiology of glucocorticoids, and the changes seen in critical illness. The reasons for the differences in establishing diagnostic criteria for adrenal insufficiency in the critically ill are also examined
A predictive analytics model for differentiating between transient ischemic attacks (TIA) and its mimics
A large cohort study of nonsteroidal anti-inflammatory drugs and renal cell carcinoma incidence in the National Institutes of Health–AARP Diet and Health Study
The role of aspirin in cancer prevention
Clinical guidelines for prophylactic aspirin use currently only consider the cardiovascular benefits of aspirin, weighed against the potential harm from aspirin-induced bleeding. Daily aspirin use has been convincingly shown to reduce the risk of colorectal cancer and recurrence of adenomatous polyps, but in average-risk populations, these benefits alone do not outweigh harms from aspirin-induced bleeding. Recently published secondary analyses of cardiovascular trials provide the first randomized evidence that daily aspirin use may also reduce the incidence of all cancers combined, even at low doses (75-100 mg daily). This Review considers the general mechanism of action that defines aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs) as a class, the specific advantages of aspirin over other NSAIDs for prophylactic use, the current evidence concerning the main health outcomes affected by aspirin use, and the hypothesis that inhibition of platelet activation may mediate both the cardioprotective and cancer-preventive effects of low-dose aspirin. It also considers how even a 10% reduction in overall cancer incidence beginning during the first 10 years of treatment could tip the balance of benefits and risks favourably in average-risk populations